2022
Human herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristics
Gisriel SD, Yuan J, Braunberger RC, Maracaja DLV, Chen X, Wu X, McCracken J, Chen M, Xie Y, Brown LE, Li P, Zhou Y, Sethi T, McHenry A, Hauser RG, Paulson N, Tang H, Hsi ED, Wang E, Zhang QY, Young KH, Xu ML, Pan Z. Human herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristics. Modern Pathology 2022, 35: 1411-1422. PMID: 35562413, PMCID: PMC9926946, DOI: 10.1038/s41379-022-01091-x.Peer-Reviewed Original ResearchConceptsLarge B-cell lymphomaDistinct clinicopathologic characteristicsMedian overall survivalB-cell lymphomaOverall survivalClinicopathologic characteristicsPrimary effusion lymphomaHHV8 infectionLymphomatous effusionsNon-germinal center B-cell subtypeLonger median overall survivalUnique clinicopathologic characteristicsFavorable prognostic factorEpstein-Barr virusSeparate diagnostic criteriaHuman herpesvirus 8B-cell subtypeMulti-institutional studyNon-Japanese casesDiagnostic uniformityImmunocompetent patientsPericardial effusionPericardial involvementSelect patientsChemotherapy administration
2021
Impact of Molecular Features of Diffuse Large B-Cell Lymphoma on Treatment Outcomes with Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy
Hill B, Roth C, Kositsky R, Dave T, Love C, McKinney M, Galal A, Neff J, Mian A, Kendall E, Ondrejka S, Chiaramonte M, Bhagat G, Ofori K, Reshef R, Kovach A, Sethi T, Mason E, Bhaskar S, Oluwole O, Pallas C, Ghosh N, Ferdman R, Chen G, Hernandez-Ilizaliturri F, Zurko J, Cunningham A, Shah N, Hu B, Stephens D, Ghosh M, Bailey N, Patel K, Pagel J, Kannan K, Hsi E, Vaidya R, Ip A, Goy A, Kambhampati S, Ohgami R, Andreadis C, Thacker E, Rozzi C, Parker C, Happ L, Dave S. Impact of Molecular Features of Diffuse Large B-Cell Lymphoma on Treatment Outcomes with Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy. Blood 2021, 138: 165. DOI: 10.1182/blood-2021-145764.Peer-Reviewed Original ResearchCAR T-cell therapyDiffuse large B-cell lymphomaChimeric antigen receptor T-cell therapyLarge B-cell lymphomaT-cell therapyCAR-T therapyB-cell lymphomaInferior PFSR diseaseBristol-Meyers SquibbCurrent equity holderADC therapeuticsCell therapySpeakers bureauBristol-Myers SquibbKite PharmaDLBCL patientsTreatment outcomesAnti-CD19 chimeric antigen receptor (CAR) T-cell therapyCD19 chimeric antigen receptor (CAR) T-cell therapyIntroduction Diffuse large B-cell lymphomaPre-treatment tumor biopsiesRelapsed/refractory (R/R) diseaseCAR T-cell infusionAdvisory CommitteePrimary sinonasal large B cell lymphoma is as histopathologically heterogeneous as systemic large B cell lymphoma but may show subtype-specific tropism for specific sinonasal anatomic sites
Desai M, Sethi T, Yenamandra A, Morgan D, Thompson M, Reddy N, Kovach A. Primary sinonasal large B cell lymphoma is as histopathologically heterogeneous as systemic large B cell lymphoma but may show subtype-specific tropism for specific sinonasal anatomic sites. Journal Of Hematopathology 2021, 14: 269-275. DOI: 10.1007/s12308-021-00473-5.Peer-Reviewed Original ResearchLarge B-cell lymphomaB-cell lymphomaHigh-grade B-cell lymphomaCell lymphomaSinonasal tractDLBCL-NOSAnatomic sitesAnatomic locationExtranodal NK/T-cell lymphomaNK/T-cell lymphomaGerminal center B-cell phenotypeMaxillary sinus tumorsT-cell lymphomaB-cell phenotypeClassification of lymphomasNon-GCB tumorsStage IIEFemale patientsSinus tumorLymphoma characteristicsSitu hybridization studiesWHO criteriaNasopharyngeal diseaseWHO classificationVariable presentation
2019
Combination of Nivolumab, Lenalidomide and Rituximab in Relapsed/Refractory Non-Germinal Center Diffuse Large B Cell Lymphoma: Results from a Dose-Escalation Cohort
Sethi T, Kovach A, Mason E, Chen H, Moyo T, Oluwole O, Morgan D, Reddy N. Combination of Nivolumab, Lenalidomide and Rituximab in Relapsed/Refractory Non-Germinal Center Diffuse Large B Cell Lymphoma: Results from a Dose-Escalation Cohort. Blood 2019, 134: 4100. DOI: 10.1182/blood-2019-129634.Peer-Reviewed Original ResearchOverall response rateProgression-free survivalDiffuse large B-cell lymphomaLarge B-cell lymphomaCombination of nivolumabDose-escalation cohortsNon-GCB DLBCLPrimary refractory diseaseB-cell lymphomaOverall survivalDay 1Prior linesRefractory diseaseCell lymphomaNon-germinal center diffuse large B-cell lymphomaSingle-arm open-label studyResponse rateAutologous stem cell transplantCommon grade 3/4 toxicitiesMedian progression-free survivalNon-germinal centre DLBCLAnti-PD-1 antibodyDiffuse large B-cell lymphoma patientsLarge B-cell lymphoma patientsCAR T-cell therapy